I. CODE OF FEDERAL REGULATIONS - 67.113(c); 67.213(c); and 67.313(c)

II. MEDICAL HISTORY: Item 37: Vascular System
The applicant should provide history as to why the medication is used. If taken for a cardiac condition, see that section. The AME should inquire if the applicant has ever experienced any side effects that could interfere with aviation safety.

III. AEROMEDICAL DECISION CONSIDERATIONS:
See Item 37: Vascular system

IV. PROTOCOL: N/A

V. PHARMACEUTICAL CONSIDERATIONS
- Cholesterol Medication
  - All drug classes require the minimum standard 48-hour initial ground trial.

### ACCEPTABLE
(As a single agent or in any combination product.)

- **HMG-CoA reductase inhibitor**
  - atorvastatin (Lipitor; Sortis [INTL])
  - fluvastatin (Lescol)
  - lovastatin (Altoprev)
  - pravastatin (Pravachol)
  - rosuvastatin (Crestor)
  - simvastatin (Zocor)
- **Fibric Acid**
  - fenofibrate (Antara, Tricor, Triglide, Trilipix)
  - gemfibrozil (Lopid)
- **Bile Acid Sequestrant**
  - cholestyramine (Prevalite; Questran)
  - colesevaleam (Welchol)
  - colestipol (Colestid)
- **Omega-3-acid ethyl esters**
  - omega-3-acid ethyl esters (Lovaza)
  - icosapent ethyl (Vascepa)
- **Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitor**
  - bempedoic acid (Nexletol)
- **Nicotinic acid**
  - niacin (Niaspan)
- **2-Azetidinone**
  - ezetimibe (Zetia)

### CONDITIONALLY ACCEPTABLE

<table>
<thead>
<tr>
<th>Medication</th>
<th>Post-dose observation (no-fly time after each dose)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoclonal Antibody - PCSK9 Inhibitor</td>
<td>4 hours</td>
</tr>
<tr>
<td>• alirocumab (Praluent)</td>
<td></td>
</tr>
<tr>
<td>• evolocumab (Repatha)</td>
<td></td>
</tr>
</tbody>
</table>

### UNACCEPTABLE

- **Apolipoprotein B Antisense Oligonucleotide**
  - mipomersen (Kynamro)